Obermatt
See Similar Stocks →

Organogenesis

NAQ:ORGO · US68621F1021
BiotechnologyMedium

360

75
Profit price1
Owner Earnings Yield88
Dividend Yield1
Price/Sales87
EV / Gross Profit94
Price/Book51
Return on Capital87
Cash Return on Capital88
Return on Equity89
EBIT Margin78
Gross Profitability97
Accruals48
Owner Earnings Margin85
Sales growth4
Profit growth19
Reinvestment58
Price momentum27
Debt load72
Refinancing98
Debt Payback100
Liquidity95
Analyst ratings7
Opinion Changes88
Price Target Upside7
Market mood61
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Organogenesis generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQCM
Websiteinvestors.organogenesis.com
ISINUS68621F1021
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Biomedical EngineeringPain ManagementHealth DiagnosticsChronic DiseasesStem Cell TherapyWellness and RecoveryOrthopaedicsSurgeryBiotechnologyHealth CareManufacturing

Description

Organogenesis Holdings Inc., a regenerative medicine company, focuses on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets. Several of the company’s e…

Analysis

Quality compounder

Organogenesis Holdings Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is expensive. The owner-earnings multiple stands at 36.6×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is adequate. The company scores 14/20 on our value-creation score: strong value creator.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
87
—
—
—
Price/Earnings
74
—
—
—
Price/Book
51
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
88
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Organogenesis with its peers
MiMedx
NAQ:MDXG
77
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Solstice Advanced Materials
NSQ:SOLS
8
CountryUSA
IndustryChemicals
SizeLarge
Full Stock Analysis →
Pulse Biosciences
NAQ:PLSE
45
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Caris Life Sciences
NSQ:CAI
93
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pioneer Power Solutions
NAQ:PPSI
16
CountryUSA
IndustryElectrical Equipment
SizeSmall
Full Stock Analysis →
Medline
NSQ:MDLN
33
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →